This podcast spotlights Owlstone Medical, a company out of Cambridge, UK which has developed technologies including the ReCIVA breath samples, Breath Biopsy, and FAIMS technology that have accelerated advancements in the collection and metabolomics analysis of exhaled breath volatile organic compounds or VOCs. These technologies are currently being used to investigate airway diseases including Asthma, COPD, IPF and Lung Cancer.